Bio-Techne Corp (NASDAQ:TECH) – Equities researchers at Leerink Swann increased their FY2018 earnings per share estimates for shares of Bio-Techne Corp in a report released on Wednesday. Leerink Swann analyst P. Souda now expects that the biotechnology company will earn $3.76 per share for the year, up from their previous forecast of $3.75. Leerink Swann also issued estimates for Bio-Techne Corp’s FY2019 earnings at $4.21 EPS.

Bio-Techne Corp (NASDAQ:TECH) last issued its earnings results on Tuesday, May 2nd. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.93 by $0.04. The company had revenue of $144.04 million during the quarter, compared to analysts’ expectations of $142.83 million. Bio-Techne Corp had a return on equity of 13.80% and a net margin of 12.86%. The firm’s quarterly revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.01 EPS.

WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/07/16/leerink-swann-comments-on-bio-techne-corps-fy2018-earnings-tech-updated-updated-updated.html.

Earnings History and Estimates for Bio-Techne Corp (NASDAQ:TECH)

A number of other equities analysts have also recently weighed in on the company. BidaskClub cut Bio-Techne Corp from a “buy” rating to a “hold” rating in a report on Tuesday. Zacks Investment Research raised Bio-Techne Corp from a “sell” rating to a “hold” rating in a research report on Saturday, May 6th. TheStreet raised Bio-Techne Corp from a “c+” rating to a “b” rating in a research report on Tuesday, May 2nd. Deutsche Bank AG reissued a “buy” rating and set a $122.00 price target (up previously from $115.00) on shares of Bio-Techne Corp in a research report on Wednesday, May 3rd. Finally, Citigroup Inc. reissued a “buy” rating and set a $125.00 price target (up previously from $115.00) on shares of Bio-Techne Corp in a research report on Wednesday, May 3rd. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $122.60.

Shares of Bio-Techne Corp (TECH) opened at 111.63 on Friday. The stock has a market capitalization of $4.17 billion, a PE ratio of 60.05 and a beta of 0.83. Bio-Techne Corp has a one year low of $95.68 and a one year high of $117.42. The firm has a 50-day moving average price of $111.25 and a 200 day moving average price of $105.38.

The business also recently announced a quarterly dividend, which was paid on Friday, June 2nd. Stockholders of record on Friday, May 19th were given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 1.15%. The ex-dividend date of this dividend was Wednesday, May 17th. Bio-Techne Corp’s payout ratio is 68.82%.

In other news, Director Karen A. Holbrook sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $111.15, for a total value of $555,750.00. Following the completion of the sale, the director now owns 6,973 shares of the company’s stock, valued at $775,048.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 10,300 shares of company stock valued at $1,145,136 in the last ninety days. Company insiders own 2.70% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Israel Discount Bank of New York acquired a new position in Bio-Techne Corp during the first quarter valued at approximately $105,000. Flinton Capital Management LLC boosted its position in Bio-Techne Corp by 10.0% in the first quarter. Flinton Capital Management LLC now owns 1,056 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 96 shares during the period. O Shaughnessy Asset Management LLC boosted its position in Bio-Techne Corp by 7.7% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,092 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 78 shares during the period. Israel Discount Bank of New York GFN acquired a new position in Bio-Techne Corp during the fourth quarter valued at approximately $127,000. Finally, Meadow Creek Investment Management LLC boosted its position in Bio-Techne Corp by 10.0% in the first quarter. Meadow Creek Investment Management LLC now owns 1,452 shares of the biotechnology company’s stock valued at $148,000 after buying an additional 132 shares during the period. Institutional investors and hedge funds own 96.99% of the company’s stock.

About Bio-Techne Corp

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.